Observes treatment outcomes in people with relapsed multiple myeloma
Looks at adults with multiple myeloma no longer responding to lenalidomide and anti-CD38 antibodies.
Plain-language title generated from the registry record
Registry title: DAratumumab and REvlimid REfractory MM
Key facts
- Where
- Pavia, ItalySee the site
Where in Italy
- Irccs San Matteo PaviaPavia, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Trial code
- NCT06541860
- Record updated
- 7 August 2024
- Original description
Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.Read full original descriptionShow less
Salvage Regimens in Multiple Myeloma Patients Double Refractory to Lenalidomide and MoAbs: Evidence From Real World Experience
Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.
Inclusion: Phase I; Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme; Patients aged ≥ 18 years; Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data; Phase II; Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes; Patients aged ≥ 18 years; Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data.
Exclusion: Patients not willing to consent to review of clinical data.